45 results about "Mesangial cell" patented technology

The invention discloses and claims benzimidazole compounds of formula (I):

wherein X is C—R2; Y is C—R2 or C—R3; W and Z are each C—R3; R1 is an optionally substituted aryl, heteroaryl or a saturated 5- or 6-membered monocyclic heterocyclic radical or a bicyclic heterocyclic radical; and A5 is H or alkyl; or a stereoisomer, a racemate, an enantiomer or a diastereoisomer of said compound of formula (I) or a pharmaceutically acceptable salt thereof; the use of compounds of formula (I) for the treatment of a disorder of proliferation of blood vessels, uncontrolled angiogenesis, a fibrotic disorder, a disorder of proliferation of mesangial cells, a metabolic disorder, allergy, asthma, thrombosis, a disease of the nervous system, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration, solid tumors and cancers, pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable adjuvants or diluents and pharmaceutical compositions comprising a compound of formula (I) and one or more. antimitiotic agents.

A novel cell seeded hollow fiber bioreactor is described as a potential bioartificial kidney. Endothelial cells along with pericyte, vascular smooth muscle, and/or mesangial cells or any mesenchymally derived support cells are seeded along a hollow fiber in a perfused bioreactor to reproduce the ultrafiltration function and transport function of the kidney. Maintenance of tissue specific function and ultrastructure suggest that this bioreactor provides an economical device for treating renal failure.

The invention provides a glomerulus-targeted protein nanoparticle pharmaceutical composition and an application thereof. The protein nanoparticle pharmaceutical composition is mainly prepared from a protein ingredient, a pharmacological active substance and a stabilizer, and the grain size of the protein nanoparticle pharmaceutical composition ranges from 10nm to 170nm. With the application of the pharmaceutical composition, passive targeted drug delivery of glomerular mesangial cells is achieved, and the aggregation concentration of a drug in a glomerulus is obviously improved or the aggregation duration of the drug in the glomerulus is prolonged, so that the curative effect of the drug is remarkably improved, and meanwhile, the toxic and side effects of the drug on a non-targeted part are greatly reduced.

This invention is directed to a compound of Formula I

or a pharmaceutically acceptable salt thereof, wherein R¹, R², R³, R⁴ and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

The invention belongs to the field of biological recognition, and discloses a cell detection method, device and apparatus for a glomerular pathological section image, and the method comprises the steps: obtaining a to-be-detected glomerular pathological section image; inputting the to-be-detected glomerular pathological section image into a preset neural network model for identification and detection, with the preset neural network model being obtained by training a neural network through a predetermined number of glomerular pathological section images for identifying and labeling mesangial cells, endothelial cells and podocytes; respectively outputting probability graphs of mesangial cells, endothelial cells and podocytes in the glomerular pathological section image to be detected from three output channels of a preset neural network model; and calculating the number of the mesangial cells, the endothelial cells and the podocytes in the glomerular pathological section image to be detected according to the probability graphs of the mesangial cells, the endothelial cells and the podocytes. The causes and conditions of the patient are determined according to the number of mesangial cells, endothelial cells and podocyte, and a treatment scheme is made accurately.

The invention discloses an application of Eucommia lignans in preparing medicaments for preventing and treating hypertension-induced renal injury. The Eucommia lignans are extracted from Eucommia barks as raw materials and used to prepare medicaments for preventing and treating hypertension-induced renal injury. The Eucommia lignans can better improve the damage of the renal glomeruli and tubules due to spontaneous hypertension and have the pharmacological action of inhibiting the expression of type III collagen and the proliferation of mesangial cells, so as to effectively prevent and treat hypertension-induced renal injury.

The invention discloses a mesangial cell image processing method, which comprises the following steps of: dividing an image to be identified into an R-channel image, a G-channel image and a B-channelimage, and extracting a mesangial region from the G-channel image to obtain a mesangial grey-scale map; extracting a cell nucleus region from the R channel image to obtain a cell nucleus grey-scale map; and performing hole filling on the mesangial grey-scale map to obtain a filled mesangial grey-scale map, and finally, performing image intersection processing on the cell nucleus grey-scale map andthe filled mesangial grey-scale map to obtain a mesangial cell region image. And a mesangial cell region image can be better positioned through different identification degrees in different channels.The invention further discloses a mesangial cell image processing device, related computer equipment and a storage medium.

This invention is directed to a compound of Formula I

or a pharmaceutically acceptable salt thereof, wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

A gene expressed specifically in mesangial cells. A DNA expressed specifically in mesangial cells; a protein encoded by this DNA; an antibody binding to this protein, etc. These substances are indigenous to mesangial cells and, therefore, useful in, for example, identifying mesangial cells and detecting abnormalities in mesangial cells. Moreover, the above protein would be helpful for clarification of the functions of masangial cells and, in its turn, for clarification of the causes of diseases relating to masangial cells. This protein is expectedly applicable to the treatment and diagnosis of diseases relating to masangial cells.

The invention discloses a cordyceps cicadae polysaccharide, a preparation method and application thereof in preparation of a medicament for preventing renal interstitial fibrosis. The method comprisesthe following steps: pulverizing cordyceps cicadae fruiting bodies, and performing sieving to obtain cordyceps cicadae fruiting body powder; ultrasonically extracting the fruiting body powder with distilled water, and then carrying out ultrahigh pressure treatment; preparing crude polysaccharide of the cordyceps cicadae fruiting body after the treatment; and then performing separation by using DEAE-cellulose anion column chromatography, and performing freeze-drying to obtain the purified polysaccharide. The method successfully prepares the cicada cordyceps polysaccharide treated and modifiedby ultrahigh pressure, and has the advantages of simple steps and higher efficiency. The intervention on a rat glomerular epithelial cell model shows that the polysaccharide can effectively inhibit the proliferation of rat glomerular epithelial cells (HMC), and has wide application prospect in the aspect of preventing renal interstitial fibrosis. The oxidation resistance of the cordyceps cicadae polysaccharide is obviously improved, and the cordyceps cicadae polysaccharide induces the apoptosis of high-glucose rat glomerular mesangial cells, has no toxicity to normal cells, and has good research value and commercial value.

The invention relates to application of sinomenine hydrochloride in promoting apoptosis of mesangial cells. Particularly, sinomenine hydrochloride can alleviate autophagy, proliferation and fibrosis of the mesangial cells caused by LPS. A combination of sinomenine hydrochloride and an autophagy inhibitor can promote the apoptosis of the mesangial cells. According to the application of sinomenine hydrochloride and the application of the combination of sinomenine hydrochloride and the autophagy inhibitor, a research basis is provided for combined treatment of kidney fibrosis disease through Chinese and Western medicine, and a good clinical application prospect is achieved.

This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.

This invention is directed to a compound of Formula I

or a pharmaceutically acceptable salt thereof, wherein R, R¹, R², R³, n, X¹, X², L¹, and L² are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

The invention discloses an application of oleanolic acid in pharmacy, and relates to the application of the oleanolic acid in the preparation of the medicine for restraining the activation of kidney fibroblast and mesangial cell, the medicine for deducing the kidney fibroblast, the medicine for improving the urine protein, the medicine for improving the kidney function, the medicine for reducing the kidney inflammation and the collagen deposition, and the medicine for reducing gene and protein related to the index of the kidney fibrosis. The invention designs a screening platform for the activation of the TGF (transforming growth factor)-beta 1-induced rat kidney fibroblast and mesangial cell, and discovers that the oleanolic acid with 4.56*10<-5>g/ml-4.56*10<-6>g/ml can restrain the activation of the TGF-beta 1-induced rat kidney fibroblast and mesangial cell. The invention further designs an in-vivo experiment of the oleanolic acid to UUO (unilateral ureteral obstruction) model rat and Platt model rat, and discovers that the oleanolic acid with the middle dose (6mg/kg/d) and the high dose (7mg/kg/d) can reduce the gene and the protein related to the urine protein, the kidney function and the kidney fibrosis of the UUO model rat and the Platt model rat.

This invention is directed to a compound of Formula I

or a pharmaceutically acceptable salt thereof, wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.